ストックスクリーナーアプリを入手
4.41
8.70%
-0.42
プレマーケット:
4.56
0.15
+3.40%
前日終値:
$4.83
開ける：
$5.08
24時間の取引高:
1.15M
Relative Volume:
4.29
時価総額：
$25.71M
収益：
-
当期純損益:
$-26.96M
株価収益率:
-0.5065
EPS:
-8.7061
ネットキャッシュフロー:
$-8.25M
1週間 パフォーマンス:
+1.38%
1か月 パフォーマンス:
+24.23%
6か月 パフォーマンス:
-46.64%
1年 パフォーマンス:
+10.39%
1日の値動き範囲:
$4.40
$6.21
1週間の範囲:
$3.51
$6.47
52週間の値動き範囲:
$2.07
$19.12
Quantum Biopharma Ltd Stock (QNTM) Company Profile
Compare QNTM vs VRTX, REGN, ARGX, ALNY, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
QNTM
Quantum Biopharma Ltd
|
4.41 | 25.71M | 0 | -26.96M | -8.25M | -8.7061 |
VRTX
Vertex Pharmaceuticals Inc
|
447.26 | 113.62B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
777.25 | 82.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
743.12 | 46.12B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.73 | 43.60B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
164.86 | 35.54B | 606.42M | -1.28B | -997.58M | -6.403 |
Quantum Biopharma Ltd (QNTM) 最新ニュース
Quantum BioPharma (QNTM) Files FDA Application for New MS Drug - GuruFocus
Quantum BioPharma Files FDA IND for Phase 2 Trial of Lucid-MS in Multiple Sclerosis - TipRanks
Quantum BioPharma submits investigational new drug (IND) application to United States Food and Drug Administration (FDA) - MarketScreener
Quantum BioPharma submits IND application for MS drug candidate - Investing.com
Quantum BioPharma (QNTM) advances Lucid-MS with FDA IND for Phase 2 MS trial - Stock Titan
Quantum BioPharma pushes MS drug toward Phase 2 with FDA filing - Stock Titan
Top Cannabis Stocks To Keep An Eye OnMarch 31st - MarketBeat
Quantum BioPharma (QNTM) Plans Phase 2 Trial for Multiple Sclero - GuruFocus
Quantum BioPharma (QNTM) Partners with Allucent for Lucid-MS Pha - GuruFocus
Quantum BioPharma (QNTM) Plans Phase 2 Trial for Multiple Sclerosis Treatment - gurufocus.com
Quantum BioPharma signs binding letter of intent with Allucent to conduct Phase 2 clinical trial in Multiple Sclerosis - MarketScreener
Quantum BioPharma Taps Allucent for Phase 2 Trial of Novel MS Drug Lucid-MS - tipranks.com
Quantum BioPharma And Allucent Enter Binding Letter Of Intent For Phase 2 Clinical Trial In Multiple Sclerosis - MarketScreener
Quantum BioPharma partners with Allucent for MS drug trial By Investing.com - Investing.com Australia
Quantum BioPharma Partners with Allucent to Advance Phase 2 Clinical Trial of Lucid-MS for Multiple Sclerosis Treatment - Quiver Quantitative
Quantum BioPharma (QNTM) lines up Allucent for Lucid-MS Phase 2 trial - Stock Titan
New MS treatment targeting demyelination moves toward Phase 2 - Stock Titan
Portfolio Recap: Will Quantum BioPharma Ltd stock benefit from M A2026 Breakouts & Breakdowns & Safe Capital Growth Plans - baoquankhu1.vn
Quantum BioPharma Raises C$3.75 Million and Converts Debt in Capital Restructuring Push - TipRanks
Institution Moves: Will Quantum BioPharma Ltd outperform during market rallies - baoquankhu1.vn
Promising Cannabis Stocks To Add to Your WatchlistMarch 28th - MarketBeat
Can Quantum BioPharma Ltd generate free cash flow2026 Sector Review & Technical Pattern Based Buy Signals - baoquankhu1.vn
Quantum Biopharma Provides Corporate Update - Sahm
Quantum BioPharma Posts Strong 2025 Results, Extends Cash Runway and Advances MS and Alcohol Health Programs - TipRanks
Top Cannabis Stocks To Watch TodayMarch 27th - MarketBeat
Quantum BioPharma reports $11.3M cash, runway to January 2028 By Investing.com - Investing.com Canada
Quantum Biopharma Maintains No Going Concern Status in Audited Financial Results for Fiscal Year 2025 - geneonline.com
Quantum BioPharma reports $11.3M cash, runway to January 2028 - Investing.com
Quantum BioPharma Ltd. Completes Phase 1 Trial for MS Drug Lucid-21-302 and Publishes unbuzzd™ Clinical Trial Results - Quiver Quantitative
Quantum Biopharma’s 2025 Audited Year End Financial Results Maintain ‘No Going Concern’ Status - MarketScreener
[6-K] Quantum Biopharma Ltd. Current Report (Foreign Issuer) | QNTM SEC FilingForm 6-K - Stock Titan
Quantum BioPharma names principal investigator for MS trial By Investing.com - Investing.com Australia
Quantum BioPharma (FRA:0K91) NonCurrent Deferred Revenue : €0.00 Mil (As of Sep. 2025) - GuruFocus
Quantum Biopharma Ltd. Subordinate Voting Shares Class B Balance Sheet – HAM:0K91 - TradingView
Quantum Biopharma Ltd. Subordinate Voting Shares Class B - TradingView
Quantum Biopharma's 2025 Audited Year End Financial Results Maintain 'No Going Concern' Status - Bitget
Quantum BioPharma Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Quantum BioPharma (Nasdaq: QNTM) outlines 2025 drug-development and IP risks - Stock Titan
Diluted earnings per share (diluted EPS) of Quantum Biopharma Ltd. Subordinate Voting Shares Class B – HAM:0K91 - TradingView
Cannabis Stocks To ResearchMarch 26th - MarketBeat
Quantum BioPharma Taps MS Expert to Lead Phase 2 Trial of Lucid-MS - TipRanks
Quantum BioPharma announces appointment of principal investigator for planned phase 2 clinical trial of Lucid-21-302 (Lucid-MS) in multiple sclerosis - MarketScreener
Quantum Biopharma Announces Appointment of Principal Investigator for Planned Phase 2 Clinical Trial of Lucid-21-302 (Lucid-MS) in Multiple Sclerosis - The Manila Times
Quantum BioPharma (QNTM) advances Lucid-MS plan, details unbuzzd™ royalties and tax assets - Stock Titan
Quantum Biopharma Announces Appointment of Principal - GlobeNewswire
Best Cannabis Stocks To Watch NowMarch 25th - MarketBeat
Market Outlook: Should I hold or sell Quantum BioPharma Ltd now2026 Setups & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
Cannabis Stocks To Add to Your WatchlistMarch 24th - MarketBeat
Quantum BioPharma publishes study on alcohol supplement unbuzzd By Investing.com - Investing.com Australia
Quantum Biopharma Ltd. Announces Peer-Reviewed Publication of Clinical Trial Results for Unbuzzd - MarketScreener
Quantum BioPharma publishes study on alcohol supplement unbuzzd - Investing.com
Quantum Biopharma Ltd (QNTM) 財務データ
収益
当期純利益
現金流量
EPS
1.52%
0.51%
大文字化:
|
ボリューム (24 時間):